title: Treatment of HIV-associated nephropathy.
abstract: HIV-Associated Nephropathy (HIVAN) is the most common cause of chronic renal disease in HIV-1 infected patients. The disease occurs predominantly in blacks between the ages of 20 and 64. In this population it is currently the third leading cause of end-stage renal disease. The majority of patients with HIVAN have an AIDS-defining condition when the kidney disease is diagnosed. Without treatment they progress to end-stage renal disease within weeks to months. Patients with HIVAN should be treated with highly active antiretroviral therapy (HAART). Treatment should prolong survival and may improve or stabilize kidney function. Steroids have short-term benefits but long-term benefits have not been shown. Converting enzyme inhibitors (CEI) seem to stabilize kidney function and appear to be most effective when administered early in the course of HIVAN. A randomized controlled trial comparing HAART therapy to HAART and CEI should be performed.
authors.affiliation: Department of Medicine, Mount Sinai School of Medicine, Saint Vincents Hospital Medical Center, New York, NY 10029, USA. Jonathan.Winston@mssm.edu
authors.forename: J A
authors.initials: JA
authors.lastname: Winston
authors.forename: G C
authors.initials: GC
authors.lastname: Burns
authors.forename: P E
authors.initials: PE
authors.lastname: Klotman
mesh_terms: D016263:AIDS-Associated Nephropathy / Q000150:complications / Q000188:drug therapy*; D006801:Humans